Tempest Therapeutics Stock Analysis
| TPST Stock | USD 2.36 0.05 2.16% |
IPO Date 12th of November 2012 | 200 Day MA 6.9399 | 50 Day MA 2.8475 | Beta (2.24) |
Tempest Therapeutics holds a debt-to-equity ratio of 0.488. At this time, Tempest Therapeutics' Short Term Debt is comparatively stable compared to the past year. Long Term Debt is likely to gain to about 8.5 M in 2026, whereas Net Debt is likely to drop (14.1 M) in 2026. Tempest Therapeutics' financial risk is the risk to Tempest Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Tempest Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Tempest Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Tempest Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Tempest Therapeutics' stakeholders.
For many companies, including Tempest Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Tempest Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Tempest Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Tempest Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Tempest Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Tempest Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Tempest Therapeutics is said to be less leveraged. If creditors hold a majority of Tempest Therapeutics' assets, the Company is said to be highly leveraged.
At this time, Tempest Therapeutics' Total Stockholder Equity is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 22.8 K in 2026, whereas Issuance Of Capital Stock is likely to drop slightly above 18.3 M in 2026. . At this time, Tempest Therapeutics' Price Book Value Ratio is comparatively stable compared to the past year. Price Earnings To Growth Ratio is likely to gain to 0.32 in 2026, despite the fact that Price To Operating Cash Flows Ratio is likely to grow to (7.84). Tempest Therapeutics is undervalued with Real Value of 4.5 and Target Price of 11.0. The main objective of Tempest Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Tempest Therapeutics is worth, separate from its market price. There are two main types of Tempest Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Tempest Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tempest Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Tempest Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. Tempest Stock Analysis Notes
About 37.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.79. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tempest Therapeutics recorded a loss per share of 9.73. The entity last dividend was issued on the 10th of December 2018. The firm had 1:13 split on the 9th of April 2025. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc. Tempest Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To find out more about Tempest Therapeutics contact LLM JD at 415 798 8589 or learn more at https://www.tempesttx.com.Tempest Therapeutics Investment Alerts
| Tempest Therapeutics generated a negative expected return over the last 90 days | |
| Tempest Therapeutics has high historical volatility and very poor performance | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (33.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 37.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Thursdays Pre-Market Session - Benzinga |
Tempest Largest EPS Surprises
Earnings surprises can significantly impact Tempest Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2025-03-17 | 2024-12-31 | -0.245 | -0.31 | -0.065 | 26 | ||
2023-11-08 | 2023-09-30 | -0.57 | -0.48 | 0.09 | 15 |
Tempest Therapeutics Environmental, Social, and Governance (ESG) Scores
Tempest Therapeutics' ESG score is a quantitative measure that evaluates Tempest Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Tempest Therapeutics' operations that may have significant financial implications and affect Tempest Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Tempest Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Atlantic Trust Group, Llc | 2025-06-30 | 260 | Sbi Securities Co Ltd | 2025-06-30 | 56.0 | Bank Of America Corp | 2025-06-30 | 33.0 | Parallel Advisors, Llc | 2025-06-30 | 18.0 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 3.0 | Jane Street Group Llc | 2025-03-31 | 0.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Global Retirement Partners, Llc. | 2025-06-30 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Sabby Management Llc | 2025-06-30 | 276.6 K | Versant Venture Management Llc | 2025-06-30 | 269.8 K |
Tempest Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.38 M.Tempest Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.22) | |
| Return On Capital Employed | (1.77) | (1.68) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (1.97) | (2.07) |
Management Efficiency
Tempest Therapeutics has return on total asset (ROA) of (0.8932) % which means that it has lost $0.8932 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.0503) %, meaning that it created substantial loss on money invested by shareholders. Tempest Therapeutics' management efficiency ratios could be used to measure how well Tempest Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.22 in 2026. Return On Capital Employed is likely to gain to -1.68 in 2026. At this time, Tempest Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 12.3 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 9.7 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.79 | 0.75 | |
| Tangible Book Value Per Share | 0.79 | 0.75 | |
| Enterprise Value Over EBITDA | (6.45) | (6.13) | |
| Price Book Value Ratio | 14.25 | 14.96 | |
| Enterprise Value Multiple | (6.45) | (6.13) | |
| Price Fair Value | 14.25 | 14.96 | |
| Enterprise Value | 56.7 M | 65.6 M |
Leadership at Tempest Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 14th of February 2026, Tempest Therapeutics has the Variance of 73.6, coefficient of variation of (512.03), and Risk Adjusted Performance of (0.15). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tempest Therapeutics, as well as the relationship between them.Tempest Therapeutics Price Movement Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Extended Parabolic SAR indicator is used to determine the direction of Tempest Therapeutics's momentum and the point in time when it has higher than normal probability of directional change. It has more input parameters than standard Parabolic SAR indicator.
Tempest Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tempest Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tempest Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tempest Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tempest Therapeutics Outstanding Bonds
Tempest Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tempest Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tempest bonds can be classified according to their maturity, which is the date when Tempest Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TELUS P 37 Corp BondUS87971MBF95 | View | |
| TELUS P 46 Corp BondUS87971MBH51 | View | |
| TELUS P 28 Corp BondUS87971MBD48 | View | |
| TCN 34 13 MAY 32 Corp BondUS87971MBW29 | View |
Tempest Therapeutics Predictive Daily Indicators
Tempest Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tempest Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2509.35 | |||
| Daily Balance Of Power | 0.25 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 2.36 | |||
| Day Typical Price | 2.36 | |||
| Price Action Indicator | 0.025 | |||
| Period Momentum Indicator | 0.05 |
Tempest Therapeutics Forecast Models
Tempest Therapeutics' time-series forecasting models are one of many Tempest Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tempest Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Tempest Therapeutics Bond Ratings
Tempest Therapeutics financial ratings play a critical role in determining how much Tempest Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Tempest Therapeutics' borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (4.11) | Unlikely Manipulator | View |
Tempest Therapeutics Debt to Cash Allocation
Tempest Therapeutics currently holds 15.37 M in liabilities with Debt to Equity (D/E) ratio of 0.49, which is about average as compared to similar companies. Tempest Therapeutics has a current ratio of 2.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Tempest Therapeutics' use of debt, we should always consider it together with its cash and equity.Tempest Therapeutics Total Assets Over Time
Tempest Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Tempest Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Tempest Therapeutics Debt Ratio | 17.0 |
Tempest Therapeutics Corporate Bonds Issued
Tempest Net Debt
Net Debt |
|
About Tempest Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Tempest Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tempest shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tempest Therapeutics. By using and applying Tempest Stock analysis, traders can create a robust methodology for identifying Tempest entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (329.74) | (346.23) | |
| Operating Profit Margin | (79.85) | (83.84) | |
| Net Loss | (329.71) | (346.20) | |
| Gross Profit Margin | 0.81 | 0.86 |
Current Tempest Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tempest analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tempest analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 11.0 | Hold | 2 | Odds |
Most Tempest analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tempest stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tempest Therapeutics, talking to its executives and customers, or listening to Tempest conference calls.
Tempest Stock Analysis Indicators
Tempest Therapeutics stock analysis indicators help investors evaluate how Tempest Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tempest Therapeutics shares will generate the highest return on investment. By understating and applying Tempest Therapeutics stock analysis, traders can identify Tempest Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 39.7 M | |
| Common Stock Shares Outstanding | 27.9 M | |
| Total Stockholder Equity | 19.1 M | |
| Total Cashflows From Investing Activities | -435 K | |
| Property Plant And Equipment Net | 9.5 M | |
| Cash And Short Term Investments | 30.3 M | |
| Cash | 30.3 M | |
| Accounts Payable | 2.5 M | |
| Net Debt | -14.9 M | |
| 50 Day M A | 2.8475 | |
| Total Current Liabilities | 14.2 M | |
| Other Operating Expenses | 42 M | |
| Non Current Assets Total | 10 M | |
| Non Currrent Assets Other | 97 K | |
| Stock Based Compensation | 5.3 M |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.